At a price of $8.14 as of 4:00 p.m. ET, the dividend yield is 48.2%.

The average volume for QLT has been 88,100 shares per day over the past 30 days. QLT has a market cap of $419.4 million and is part of the drugs industry. Shares are up 4.8% year to date as of the close of trading on Tuesday.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

QLT Inc., a biotechnology company, engages in the development and commercialization of ocular products that address the unmet medical needs of patients and clinicians.

TheStreet Ratings rates QLT as a hold. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, expanding profit margins and increase in stock price during the past year. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and disappointing return on equity. You can view the full QLT Ratings Report now.

If you liked this article you might like

Wall Street Loses Gains After Fed's Unsurprising June Call

Stocks Turn Lower After Yellen Expresses Confidence in U.S. Economy

Wall Street Rises as It Awaits Fed, Crude Comes Off Lows

Stock Futures Hold Gains as Industrial Production Falls

QLT, Aegerion Merge Two Troubled Biotechs